GLP-1 'rare' side effects: what TikTok gets right and wrong

What did @glp1andwellness.bestie actually say?

The creator describes experiencing "Aladynia" (allodynia) while on a GLP-1 medication, characterizing it as skin that feels like a sunburn with no visible cause. They say it has happened "maybe six or seven times" over nine months, lasts 24 to 48 hours, and this particular week it moved across different body parts.

To their credit, they frame this carefully. They say it is "not a common side effect whatsoever," they are not trying to scare people, and they only know of one other person who has experienced this on a GLP-1. They also say it does not bother them enough to stop the medication and is "not necessarily dangerous." That is a reasonable, measured way to present a personal anecdote. The problem is in the details, specifically the name, the mechanism framing, and the implied causation.

Does the science back this up?

Allodynia is real and well-documented, but its connection to GLP-1 receptor agonists specifically is not established in clinical trial data. That gap matters more than it might seem.

Allodynia refers to pain triggered by stimuli that do not normally cause pain, like light touch or temperature. It is a recognized feature of conditions including fibromyalgia, migraines, peripheral neuropathy, and small fiber neuropathy (Oaklander et al., 2003, Muscle and Nerve). It is not a named, listed side effect in the prescribing information for semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro).

What GLP-1 trials do report in the nervous system category are headaches and, less commonly, dizziness. The STEP trials for semaglutide (Wilding et al., 2021, NEJM) and the SURMOUNT trials for tirzepatide (Jastreboff et al., 2022, NEJM) did not list allodynia or skin hypersensitivity as adverse events. That absence does not mean it cannot happen, but it means we have no good data confirming GLP-1 drugs cause it.

What did they get wrong (or right)?

The creator spelled and pronounced it wrong throughout, calling it "Aladynia." That is a minor issue on its own, but it matters here because viewers searching for information will not find it. More substantively, they describe it as "a neuropathic pain or dysfunction" which is not wrong exactly, but allodynia is a symptom, not a condition. Calling it a side effect of the GLP-1 without any qualifying language about causation is the bigger issue.

The migratory pattern they describe, moving from shoulders to forearm to hip over a week, is not typical of how allodynia is usually reported in the literature. That pattern might suggest something unrelated to the medication entirely, such as a migraine variant, a connective tissue issue, or even stress-related sensitization.

What they got right: they were appropriately humble about how rare this is, they did not catastrophize, and they were transparent that they cannot confirm anyone else has had this. That is better than most anecdotal side effect content on TikTok.

What should you actually know?

If you are on a GLP-1 and experiencing skin hypersensitivity or unusual pain, do not self-diagnose from a TikTok comment section. There are real conditions that cause allodynia, some of which warrant medical evaluation, including small fiber neuropathy, which is actually associated with obesity and metabolic syndrome (Callaghan et al., 2012, Diabetes Care), not necessarily with the GLP-1 drug itself.

It is also worth knowing that GLP-1 receptor agonists do have neurological activity. GLP-1 receptors are expressed in the central and peripheral nervous system (Holst, 2007, Physiological Reviews), so it is biologically plausible that these drugs could affect pain signaling in some patients. Plausible is not the same as proven.

• Report any new or unusual neurological symptoms to your prescriber, not your comment section.
• The FDA MedWatch system exists specifically for reporting side effects that are not listed in prescribing information.
• Do not stop a GLP-1 medication because of a TikTok video without speaking to a clinician first.